Forty patients with post-hepatitis C virus ( HCV ) end-stage liver disease were randomized into two groups : Group 1 ( GI ) : 20 patients who received granulocyte colony-stimulating factor ( G-CSF ) for 5days followed by autologous MSCs peripheral-vein infusion and group 2 ( GII ) : 20 patients who received regular liver-supportive treatment only ( control group ) .